Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Multi-target intervention and synergistic treatment are critical for the drug development of Alzheimer’s disease (AD) due to its complex and multifactional nature. Oxidative stress and amyloid β peptides (Aβ) accumulation have been recognized as therapeutic targets for AD. Herein, with ability to inhibit Aβ aggregation and the broad-spectrum antioxidant properties, the large amino acid mimicking selenium-doped carbon quantum dots (SeCQDs) are presented as novel nanoagents for multi-target therapy of AD. Compared with the precursor, selenocystine, SeCQDs which maintain the intrinsic properties of both selenium and carbon quantum dots (CQDs) possess good biocompatibility and a remarkable ROS-scavenging activity. Moreover, the functionalized α-carboxyl and amino groups on edge of SeCQDs can trigger multivalent interactions with Aβ, leading to the ability of SeCQDs to inhibit Aβ aggregation. In vivo study demonstrated that SeCQDs can significantly ameliorate the Aβ induced memory deficits, reduce Aβ accumulation and inhibit neuron degeneration in AD model rats. The versatility of functionalization and potential ability to cross the blood-brain barrier (BBB) make SeCQDs as prospective nanodrugs for treating AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“The main pathological features of AD are the accumulation of extracellular plaques consisting of amyloid β peptides (Aβ) and the formation of neurofibrillary tangles which are composed of hyperphosphorylated tau filaments in the brain (Palop and Mucke, 2010; Zhang et al., 2019; Kim et al., 2020).”
BackgroundZhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R. G., Zhang, S., Abdelmohsen, K., Bohr, V. A., Misra Sen, J., Gorospe, M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0372-9 · Cited by 977 · cited 4×
“…peptides, peptide aggregation, anti-oxidant activity, multi-target therapy INTRODUCTION Alzheimer’s disease (AD) as one of the most prevalent types of dementia has been reported to affect approximately 10% of people aged 65 years or more (Palop andMucke, 2010; Zhang et al., 2019; Kim et al., 2020).”
BackgroundInfluentialHou, K., Zhao, J., Wang, H., Li, B., Li, K., Shi, X., Wan, K., Ai, J., Lv, J., Wang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18525-2 · Cited by 373 · cited 1×
“Progressive cognitive declines, the main clinical symptoms of AD, have been reported to be directly correlated with Aβ-mediated synaptic deficits (Beckman et al., 2019; Hou et al., 2020; Samanta et al., 2021).”
BackgroundOligomeric Aβ in the monkey brain impacts synaptic integrity and induces accelerated cortical aging
Beckman, D., Ott, S., Donis-Cox, K., Janssen, W. G., Bliss-Moreau, E., Rudebeck, P. H., Baxter, M. G., & Morrison, J. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902301116 · Cited by 111
Cited by
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Lin, X., Liu, W., Dong, X., & Sun, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.063 · Cited by 44
Wei, Z., Dong, X., & Sun, Y. (2024) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.113907 · Cited by 36
Metadata
- Authors
- Zhou, X., Hu, S., Wang, S., Pang, Y., Lin, Y., & Li, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-10-27
- Volume
- 12
- Pages
- 778613-778613
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3210391685
- Cited by
- 46
- References
- 5
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fphar.2021.778613
- The paper
- Zhou, X., Hu, S., Wang, S., Pang, Y., Lin, Y., & Li, M. (2021). Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.778613
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.